In summary, during the last decade by far the most spectacular gain is obtained in HER2/neu-overexpressing MBC. Introduction of bevacizumab being a VEGF-directed qualified procedure continues to be a difficulty on discussion. Some of the novel therapeutics into the breast cancer armamentarium resulted in prolongation of survival for patients https://masono520gpv6.wikibyby.com/user